Management

Stephane Degove; portrait of CEO and co-founder at Atamyo Therapeutics

Stéphane Degove

Co-founder
& Chief Executive Officer

Stephane Degove; portrait of CEO and co-founder at Atamyo Therapeutics

Stéphane Degove

Co-founder & Chief Executive Officer

Stéphane is a biotech entrepreneur with a 25 years experience in pharma/biotech and strategy. He graduated from ESCP (majoring in Finance), worked at Sanofi in Finance and was co-founder and CFO in 2003 of a biotechnology company in cancer and thrombosis, Endotis Pharma. He co-founded in 2013 and was CEO of an immuno-oncology biotech, Gamamabs Pharma. Under his leadership, Endotis Pharma and GamaMabs Pharma raised € 70 million from international funds and built portfolios of innovative products developed up to Phase II.

View Bio
Isabelle Richard, portrait or Chief Scientific Advisor and co-founder at Atamyo

Isabelle Richard, Ph. D

Co-founder
& Chief Scientific Officer

Isabelle Richard, portrait or Chief Scientific Advisor and co-founder at Atamyo

Isabelle Richard, Ph. D

Co-founder & Chief Scientific Officer

Dr. Isabelle RICHARD is a research Director at the CNRS. She is heading the Muscular Dystrophy team within the INSERM unit U951 at Genethon, Evry, France. Isabelle Richard is an expert in neuromuscular diseases and a pioneer in the research on LGMDs and in the development of gene therapy targeting LGMDs. She has published more than 160 scientific papers on muscular dystrophies. Among the most important highlights: identification of calpain 3 as the first gene implicated in an LGMD, demonstration of the heterogeneity of this group of diseases, participation in the identification of the gene of all the frequent LGMDs, proof-of-principle of the efficiency of gene therapy for all the most frequent LGMDs.

View Bio

Board of Directors

Frédéric Revah, Ph.D., CEO,

Genethon

Alexandre Lemoalle, Director of Strategic Projects,

Genethon

Stéphane Degove, CEO,

Atamyo